Corneal avascularity is essential for the preservation of optimal vision. However, the corneal angiogenic privilege is compromised under pathologic conditions such as hypoxia and inflammation [1-3], since the delicate balance between proangiogenic and antiangiogenic factors is lost under such conditions [4-6]. The proangiogenic factor, vascular endoth-elial growth factor (VEGF), regulates the development and maintenance of blood vessels, and is upregulated to main-tain corneal avascularity when the cornea is injured, event-u ally resulting in corneal neovascularization (NV) [6,7]. Recent animal experiments and clinical trials revealed that bevacizumab and ranibizumab, two representative VEGF inhibitors, have anti-angiogenic effects on the c...
PURPOSE. Bevacizumab is a potent recombinant humanized monoclonal antibody directed against vascular...
Bevacizumab, a 149-kDa protein, is a recombinant humanized monoclonal antibody to VEGF. PEDF, a 50-k...
Bevacizumab, a 149-kDa protein, is a recombinant humanized monoclonal antibody to VEGF. PEDF, a 50-k...
Vascular endothelial growth factor (VEGF) plays a key role in vasculogenesis and the pathologic neov...
Corneal avascularity is necessary for the preservation of optimal vision. The cornea maintains a dyn...
Background: Corneal neovascularization (CN) is a clue feature of different ocular pathological condi...
Corneal neovascularization (NV) is a severe complication associated with inflammatory or infectious ...
Corneal neovascularization is a serious condition resulting in various degrees of vision loss. The a...
To evaluate the effects and underlying mechanisms of early and late subconjunctival injection of bev...
PURPOSE: To evaluate the effects and underlying mechanisms of early and late subconjunctival injecti...
Pathologic angiogenesis is involved in cancer and several blinding conditions such as wet age-relate...
AbstractCorneal neovascularization (NV), the excessive ingrowth of blood vessels from conjunctiva in...
The avascular nature of the cornea is disrupted when corneal neovascularization (NV) causes the form...
Corneal neovascularization (NV), the excessive ingrowth of blood vessels from conjunctiva into the c...
Background: Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region i...
PURPOSE. Bevacizumab is a potent recombinant humanized monoclonal antibody directed against vascular...
Bevacizumab, a 149-kDa protein, is a recombinant humanized monoclonal antibody to VEGF. PEDF, a 50-k...
Bevacizumab, a 149-kDa protein, is a recombinant humanized monoclonal antibody to VEGF. PEDF, a 50-k...
Vascular endothelial growth factor (VEGF) plays a key role in vasculogenesis and the pathologic neov...
Corneal avascularity is necessary for the preservation of optimal vision. The cornea maintains a dyn...
Background: Corneal neovascularization (CN) is a clue feature of different ocular pathological condi...
Corneal neovascularization (NV) is a severe complication associated with inflammatory or infectious ...
Corneal neovascularization is a serious condition resulting in various degrees of vision loss. The a...
To evaluate the effects and underlying mechanisms of early and late subconjunctival injection of bev...
PURPOSE: To evaluate the effects and underlying mechanisms of early and late subconjunctival injecti...
Pathologic angiogenesis is involved in cancer and several blinding conditions such as wet age-relate...
AbstractCorneal neovascularization (NV), the excessive ingrowth of blood vessels from conjunctiva in...
The avascular nature of the cornea is disrupted when corneal neovascularization (NV) causes the form...
Corneal neovascularization (NV), the excessive ingrowth of blood vessels from conjunctiva into the c...
Background: Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region i...
PURPOSE. Bevacizumab is a potent recombinant humanized monoclonal antibody directed against vascular...
Bevacizumab, a 149-kDa protein, is a recombinant humanized monoclonal antibody to VEGF. PEDF, a 50-k...
Bevacizumab, a 149-kDa protein, is a recombinant humanized monoclonal antibody to VEGF. PEDF, a 50-k...